Kenota is revolutionizing the way we test for disease
Key people at Kenota (formerly ExVivo Labs).
Kenota (formerly ExVivo Labs) was founded in 2014 by Moufeed Kaddoura (Founder/CEO).
Kenota (formerly ExVivo Labs) was founded in 2014 by Moufeed Kaddoura (Founder/CEO).
Kenota (formerly ExVivo Labs) is a healthcare technology company focused on revolutionizing disease testing by developing rapid, accessible diagnostic tools that simplify and accelerate disease detection. Their flagship product is a rapid allergy testing system that delivers results within 30 minutes using minimally invasive methods such as finger-prick blood samples or non-invasive skin patches. Kenota primarily serves healthcare providers, clinics, and hospitals in North America, aiming to improve point-of-care diagnostics by reducing reliance on centralized labs, thus enhancing speed, convenience, and cost-efficiency in disease management[1][3][5].
Founded in 2014 by Moufeed Kaddoura in Kitchener-Waterloo, Ontario, Canada, Kenota emerged from a vision to bring advanced testing technologies directly to clinical settings. Kaddoura and his team, composed of scientists, engineers, and business professionals with extensive experience in medical diagnostics and regulatory approvals, sought to address the limitations of traditional allergy and disease testing methods. Early traction included developing non-invasive skin patch technology and rapid testing platforms, positioning Kenota as a pioneer in next-generation diagnostic tools[2][4][5].
Kenota is riding the growing trend toward decentralized, rapid diagnostics in healthcare, driven by increasing demand for point-of-care testing solutions that reduce turnaround times and improve patient outcomes. The timing is critical as healthcare systems worldwide seek to enhance infectious disease management and allergy diagnostics with more accessible, data-driven tools. Market forces such as rising chronic disease prevalence, technological advances in biosensors and microfluidics, and regulatory support for innovative diagnostics favor Kenota’s growth. By enabling faster, more convenient testing, Kenota influences the broader ecosystem by pushing healthcare toward more patient-centric, technology-enabled models[1][3].
Looking ahead, Kenota is poised to expand its product portfolio beyond allergy testing to other disease diagnostics, leveraging its platform technology and regulatory momentum. Trends such as personalized medicine, telehealth integration, and increased demand for rapid diagnostics will shape its trajectory. As Kenota scales, it may further disrupt traditional laboratory testing paradigms and strengthen its influence in the healthcare diagnostics market, particularly in North America. Its success will depend on continued innovation, regulatory approvals, and adoption by healthcare providers seeking efficient, reliable point-of-care solutions[1][3][4]. This aligns with its mission to revolutionize disease testing by making it faster, easier, and more accessible.
Key people at Kenota (formerly ExVivo Labs).
